Sanofi (SNYNF)
| Market Cap | 119.01B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | n/a |
| EPS (ttm) | 8.67 |
| PE Ratio | 11.13 |
| Forward PE | 10.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250 |
| Average Volume | 13,358 |
| Open | 97.09 |
| Previous Close | 95.85 |
| Day's Range | 97.09 - 97.09 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.37 |
| RSI | 46.91 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplac...
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplaci...
Sanofi (SNY) Gains Chinese Approval for Two Rare Disease Medications
Sanofi (SNY) Gains Chinese Approval for Two Rare Disease Medications
Sanofi (SNY) Gains Chinese Approval for Two Rare Hematology Drugs
Sanofi (SNY) Gains Chinese Approval for Two Rare Hematology Drugs
Sanofi’s Qfitlia and Cablivi get nod from China
Sanofi's Bleeding-Disorder Treatments Get Approval in China
Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
Sanofi: NMPA In China Approves Qfitlia And Cablivi
(RTTNews) - Sanofi (SNY) announced the National Medical Products Administration in China has approved two Sanofi medicines for rare hematologic diseases: Qfitlia or fitusiran for hemophilia and Cabliv...
Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six inj...
Press Release: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six inj...
InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimm...
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks
U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership tea...
SNY Analyst Downgrades: Sanofi Receives Neutral Rating from Guggenheim | SNY Stock News
SNY Analyst Downgrades: Sanofi Receives Neutral Rating from Guggenheim | SNY Stock News
Sanofi (SNY) Downgraded by Guggenheim Analyst Amidst Pipeline Concerns
Sanofi (SNY) Downgraded by Guggenheim Analyst Amidst Pipeline Concerns
Sanofi (SNY) Downgraded to Neutral by JP Morgan | SNY Stock News
Sanofi (SNY) Downgraded to Neutral by JP Morgan | SNY Stock News
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”).
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes
LONDON--(BUSINESS WIRE)-- #AI--LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic anti...
Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Sanofi SA at Citi Global Healthcare Conference Transcript
Sanofi SA at Citi Global Healthcare Conference Transcript
Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Why Falcon's Beyond Stock Is Jumping Today
Falcon’s Beyond Global, Inc. (NASDAQ: FBYD) traded higher on Tuesday after the company announced its placement on the preliminary list for possible inclusion in the Russell 2000 Index. FTSE Russell p...
Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus
Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.